Background Procalcitonin is a promising marker for identifi cation of bacterial infections. We assessed the accuracy and clinical value of procalcitonin for diagnosis of sepsis in critically ill patients.
Introduction
Worldwide, sepsis and its sequelae are still a common cause of acute illness and death in patients with community-acquired and nosocomial infections. 1, 2 The American College of Chest Physicians and the Society of Critical Care Medicine Consensus Conference (Northbrook, IL, USA; August, 1991) defi ned sepsis as systemic infl ammatory response caused by infection. 3 However, no gold standard exists for proof of infection. Bacteraemia is identifi ed in only about 30% of patients with sepsis, depending on previous antibiotic treatment. 4, 5 Furthermore, early clinical signs of sepsis, such as fever, tachycardia, and leucocytosis, are non-specifi c and overlap with signs of systemic infl ammatory response syndromes of non-infectious origin, especially in patients who have undergone surgery. Other signs, such as arterial hypotension, thrombocytopenia, or increased lactate concentrations suggest, too late for life-saving treatment, progression to organ dysfunction. Thus, delay in diagnosis and treatment of sepsis increases mortality, prolongs length of hospital stay, and increases costs, 6, 7 highlighting the need for early and reliable diagnostic biomarkers for sepsis.
Several humoral and cellular systems are activated during sepsis, with a subsequent release of various molecules that mediate the host response to infection. Several potential bloodstream biomarkers have been investigated for their ability to diagnose sepsis, estimate its severity, and provide a prognosis. The 116-aminoacid polypeptide procalcitonin had been termed the "the champion so far" for identifi cation of bacterial infections 8 because it has several advantages over other potential biomarkers-ie, wide biological range, short time of induction after bacterial stimulus, and long half-life. 9 However, only two meta-analyses have investigated the accuracy of procalcitonin for the diagnosis of sepsis, with confl icting results. 10, 11 Both were limited by selected populations, did not include a heterogeneous patient population, and, most importantly, were biased by the choice of a gold standard for the defi nition of sepsis. Additionally, new studies of procalcitonin have been done since the publication of the meta-analyses and our understanding of procalcitonin is still developing.
We did a meta-analysis to investigate the ability of procalcitonin to diff erentiate between sepsis and systemic infl ammatory response syndromes of non-infectious origin in critically ill patients and address the heterogeneity of patients and the aff ect of individual covariates.
Methods

Search strategy and selection criteria
We systematically searched Medline (via PubMed), Embase (via OvidSP), ISI Web of Knowledge, the Cochrane Library, Scopus, BioMed Central, and Science Direct for studies that assessed the accuracy of procalcitonin for the diagnosis of sepsis.
Our medical subject heading terms (for Medline), EMTREE terms (for Embase), and text (for others) were "(procalcitonin OR PCT) AND (sepsis OR "bacterial infection" OR "systemic infl ammatory response syndrome" OR SIRS)". To reduce the number of results, for searches in Science Direct, Embase, and Scopus, we also used the search terms "NOT (review OR letter OR editorial OR "animal experiment" OR "meeting abstract" OR "proceeding paper" OR "poster presentation" OR "meta-analysis" OR "case report")". We searched the databases between inception and Feb 21, 2012. We also searched the reference list of each primary study identifi ed and of previous systematic reviews.
Studies were included if they assessed the accuracy of procalcitonin for diff erentiation between critically ill patients with sepsis from those who have a systemic infl ammatory response syndrome without infection.
To be eligible, studies had to have a well defi ned reference standard for sepsis, which included the use of defi nitions established by the American College of Chest Physicians and Society of Critical Care Medicine Consensus Conference 3 or the German Sepsis Society. 12 In accordance with these defi nitions, the presence of infection had to be micro biologically confi rmed or at least clinically suspected because of one or more characteristics: white blood cells in a normally sterile body fl uid, perforated viscus, radiographic evidence of pneumonia in association with production of purulent sputum, and syndrome asso ciated with a high risk of infection (eg, ascending cholangitis).
Furthermore, the studies had to provide suffi cient information to construct the 2×2 contingency table-ie, false and true positives and negatives were provided.
We only included publications written in English, German, or French. Animal experiments, reviews, correspondences, case reports, expert opinions, and editorials were excluded. We also excluded all studies that involved healthy people, patients without probable infection, and children younger than 28 days.
Procedures
Two investigators (CW, AP) independently extracted data, including the quality assessment from the retrieved studies. Discrepancies were resolved in a consensus meeting or, if agreement could not be reached, they were resolved by referral to a third investigator (FMB).
The extracted data were general and detailed methodology characteristics, characteristics of the study population (adults or children), setting (emergency depart ment, general ward, or intensive care unit), admission category (surgical or medical), severity of illness (sepsis, severe sepsis, or septic shock), and details of the procalcitonin assays and cutoff s used.
Each investigator also recorded the number of true and false positives and negatives. We contacted the corresponding authors if further information was needed. If no response was received after sending a reminder, the study was excluded.
We assessed the methodological quality of the studies with the Quality Assessment of Diagnostic Accuracy Studies checklist. 13 We tailored the guidelines for scoring each item of the checklist to our review.
14 Because overall quality scoring is diffi cult and should not be included in meta-analyses, 15 we included only item 9 (descrip tion of the reference standard) and item 11 (diagnostic review bias) of the 14 individual quality-related items as covariates in a bivariate random-eff ects model to test them as possible sources of variation and bias.
Statistical analysis
We tabulated true positives, false negatives, false positives, and true negatives in patients with sepsis and systemic infl ammatory response syndrome, stratifi ed by study. We used the numbers to calculate sensitivity and specifi city and a corresponding CI.
To synthesise data, we used an exact binomial rendition 16 of the bivariate mixed-eff ects regression model developed by van Houwelingen 17, 18 for meta- 19, 20 This model does not transform pairs of sensitivity and specifi city of individual studies into a single indicator of diagnostic accuracy, but preserves the two-dimensional nature of the data taking into account any correlation between the two.
Based on this model, we estimated mean logit sensitivity and specifi city with their standard error and 95% CIs, the between-study variability in logit sensitivity and specifi city, and the covariance between them. We back-transformed these quantities to the original receiver operating curve scale to obtain summary sensitivity, specifi city, and diagnostic odds ratios. We then used the derived logit estimates of sensitivity, specifi city, and respective variances to construct a hierarchical summary receiver operating curve for procalcitonin with summary operating points for sensitivity and specifi city on the curves and a 95% confi dence contour ellipsoid (two-dimensional CI).
We calculated I² to assess heterogeneity. If heterogeneity among studies was recorded, the potential source of heterogeneity was investigated by metaregres sion. Study-level covariates can be used in metaregres sion to combine results from multiple studies with attention to between-study variation. We used study-specifi c covariates such as population or admission category. To investigate publication bias, we constructed eff ective sample size funnel plots versus the log diagnostic odds ratio and did a regression test of asymmetry. 21 We calculated κ statistics to assess the agreement between the two investigators for assessment of methodological quality. We used the MIDAS module 22 for STATA (version 12) for the bivariate summary receiver operating curve analysis and to calculate κ statistics. We used Proc GLIMMIX in SAS (version 9.3) to do the metaregression. Graphs were produced with the MIDAS module and the Quality Assessment of Diagnostic Accuracy Studies module for STATA.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Our database search retrieved 3487 articles. After reviewing the titles and abstracts, we excluded 3321. After a full text review we excluded a further 136, leaving 30 studies for inclusion (fi gure 1). Because in one study investigators reported diagnostic accuracy separately for medical and surgical patients, the study was divided into two parts, thus we analysed 31 datasets. Search of the reference lists of the identifi ed articles and previous systematic reviews 10, 11, 23 did not identify any more relevant articles.
The table shows the main study characteristics. 3244 critically ill patients were included in the analysis, of whom 1863 (57%) had sepsis and 1381 (43%) had systemic infl ammatory response syndrome of noninfectious origin. 21 of 30 studies reported classifi cation of severity of illness (sepsis, severe sepsis, or septic shock). Of 1173 patients, 499 (42%) had sepsis, 234 (20%) had severe sepsis, and 440 (38%) had septic shock.
The prevalence of sepsis among studies ranged between 34% and 88% (mean 60%). Only four studies were done in a paediatric setting, whereas 27 investigated adult patients (table) . Sites of infectioneg, lung, abdomen, bloodstream, urinary tract-varied. The source of infection (com munity-acquired or nosocomial) also diff ered between studies.
Most studies were done in intensive care units, four of them in a paediatric intensive care unit, and most (20 of 30) were done in Europe (table). The cutoff for procalcitonin concentration diff ered substantially between studies (median 1·1 ng/mL, IQR 0·5-2·0).
Most studies (17 of 30) used a quantitative manual procalcitonin assay for diagnosis of sepsis ( 
Table: Study characteristics
See Online for appendix checklist, 13 how the studies scored on each item, and how the items were assessed. We omitted item 12 of the checklist (clinical data) because the index test is fully automated and no further clinical data are needed to interpret the test results.
The inter-rater reliability for assessment of quality items was 0·59 (p<0·0001). Overall, the methodological quality was moderate. None of the studies fulfi lled all of the items, but all studies fulfi lled at least four items. 22 studies (73%) met at least 50% of the items. Items 3 (reference standard), 5 (partial verifi cation bias), 6 (diff erential verifi cation bias), and 14 (withdrawals) were fulfi lled by all studies. Reports of test review bias (item 10) and uninterpretable results (item 13) were poor (appendix). We identifi ed publication bias by Deeks' regression test of asymmetry (t=4·12; p<0·0005; appendix).
Pooled sensitivity was 0·77 (95% CI 0·72-0·81) and pooled specifi city was 0·79 (95% CI 0·74-0·84; fi gure 2).
The area under the receiver operating char acteristic curve was 0·85 (95% CI 0·81-0·88; fi gure 3). Substantial heterogeneity exists among the studies (overall I² for bivariate model 96%, 95% CI 94-99). We recorded no evidence of a threshold eff ect (tested with the STATA MIDAS module). The proportion of heterogeneity probably caused by diff erent cutoff s was small (0·05). To identify the source of heterogeneity, we did metaregression analyses.
To compare medical with surgical patients we did a stratifi ed bivariate regression analysis. We obtained data from 13 studies (nine provided data for medical patients and four provided data for surgical patients). The diagnostic accuracy in surgical patients was higher than that in medical patients as measured by the area under the summary receiver operating characteristic curve (0·83 [95% CI 0·80-0·86] vs 0·79 [0·75-0·83]; not tested for signifi cance). We also compared adult with paediatric 53 Tugrul and colleagues (2002) 52 Tsangaris and colleagues (2009) 51 Tsalik and colleagues (2011) 50 Suprin and colleagues (2000) 49 Simon and colleagues (2008) 48 Selberg and colleagues (2000) 47 Sakr and colleagues (2008) 46 Ruiz-Alvares and colleagues (2009) 45 Pavcnik-Arnol and colleagues (2007) 44 Oshita and colleagues (2010) 43 Naeini and colleagues (2006) 42 Meynaar and colleagues (2011) 41 Latour-Perez and colleagues (2010) 40 Kofoed and colleagues (2007) 39 Jimeno and colleagues (2004) 38 Ivancevic and colleagues (2008) 37 Hsu and colleagues (2011) 36 Harbath and colleagues (2001) 35 Groselj-Grenc and colleagues (2009) 34 Gibot and colleagues (2004) 33 Gaini and colleagues (2006) 32 Du and colleagues (2003) 31 
Dorizzi and colleagues (2006) 30
Clec'h and colleagues (2006; surgical) 29 Clec'h and colleagues (2006; medical) 29 Castelli and colleagues (2004) 28 Bell and colleagues (2003) 27 Arkader and colleagues (2006) 26 Al-Nawas and colleagues (1996) 25 Ahmadinejad and colleagues (2009) 
0·79 (0·74-0·84)
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patients (0·85 [0·82-0·88] vs 0·85 [0·81-0·88]
; not tested for signifi cance). Analysis of the other covariates yielded no signifi cant results (data not shown). Thus, the heterogeneity could not be explained by metaregression analysis.
Discussion
Procalcitonin can diff erentiate eff ectively between sepsis and systemic infl ammatory response syndrome of noninfectious origin. Previously, two meta-analyses have investigated the diagnostic accuracy of procalcitonin in critically ill patients, with confl icting results.
10,11
In a meta-analysis from 2006, including studies published between April, 1996, and October, 2004, Uzzan and colleagues 11 reported that the summary receiver operating characteristics curve for procalcitonin was better than for C-reactive protein for identifi cation of sepsis. However, the investigators restricted the popu lation to surgery or trauma patients. Therefore, no conclusion can be drawn for patients other than surgical. Furthermore, the researchers did not assess the heterogeneity of patients from diff erent settings, with diff erent sites of infection, or other study-specifi c covariates.
In a meta-analysis from 2007, including 18 studies published between April, 1996, and November, 2005, Tang and colleagues 10 concluded that procalcitonin is not able to discriminate between sepsis and systemic infl ammatory response syndrome. The diagnostic accuracy of procalcitonin was low; mean sensitivity and specifi city were both 71% (95% 67-76) and the area under the summary receiver operator characteristic curve was 0·78 (95% CI 0·73-83). However, their fi ndings were heavily biased because of their selection criteria. First, studies were excluded that had sites of infection typical in sepsis, such as abdominal sepsis, pancreatitis, or meningitis. Second, studies that assessed the ability of procalcitonin to diagnose septic shock were excluded. Because progres sion of sepsis to septic shock is associated with an increase in procalcitonin concentration, 1 exclusion of patients with septic shock could reduce the overall estimate of diagnostic accuracy. To prevent systematic bias, we included all eligible studies that investigated the diagnostic capacity of procalcitonin in the continuum from sepsis to severe sepsis and to septic shock. Third, they included studies that assessed patients who did not have systemic infl ammatory response syndrome or who were not critically ill, which might cause underestimation of diagnostic accuracy.
Accordingly, 23 studies included in the previous metaanalyses 10, 11 were excluded from our systematic review because 13 included healthy controls or patients who did not have systemic infl ammatory response syn drome in the control group, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] and seven did not provide clear defi nitions for the target condition or included patients who had infection without systemic infl am matory response syndrome and thus were not in accordance with our selection criteria. 54, [64] [65] [66] [67] [68] [69] Furthermore, four studies had insuffi cient information to construct the 2 × 2 contingency table. [70] [71] [72] [73] One investigated the predictive value of procalcitonin for tumour necrosis factor α and interleukin 6 concentrations. 74 Another did multiple measurements in several patients 75 and one study investigated the prognostic value of procalcitonin for infection after cardiac surgery. 76 Furthermore, the meta-analysis of Tang and colleagues 10 has substantial shortcomings in its quantitative data analysis. It summarised pairs of sensitivity and specifi city into a single measure of diagnostic accuracy. Thus, important information is missing. To retain the two-dimensional character, we used the bivariate mixedeff ects regression model.
Our meta-analysis has several limitations. 77 First, we detected substantial heterogeneity between studies but none of the study characteristics were responsible for the majority of this heterogeneity. The studies diff er in several ways-eg, methodological quality, patients' clinical spectrum, admission category, and procalcitonin assay used. Thus, further unrecorded diff erences between the studies probably contribute to the heterogeneity. Use of a more homogenous population would solve this diffi culty, but would cause selection bias.
Second, a reliable test of infection is still absent, so observational studies are biased by the choice of gold standard. According to our inclusion criteria, the presence of infection had to be microbiologically confi rmed or at least clinically suspected. All included studies fulfi lled this requirement (appendix), but most did not provide much detailed information about how infection was proved. Nevertheless, depending on previous antibiotic treatment, bacteraemia occurs in only about 30% of patients with sepsis. 4, 5 Additionally, absence of standardisation of clinical and radiological fi ndings could cause interobserver variability, which could lead to false-negative or false-positive judgments about the patient's medical condition. We only included studies that had a well defi ned reference standard for sepsis. Nevertheless, we do not know defi nitively whether all patients with infection were identifi ed as such.
Third, implementation of some studies was reported poorly, especially with regard to uninterpretable results and test review bias (appendix). To minimise resultant bias and to ensure more homogeneity, investigators should use the Standards for Reporting of Diagnostic Accuracy checklist 78 and also consider using the Quality Assessment of Diagnostic Accuracy Studies checklist. 13 Fourth, we detected publication bias. Studies with desirable results are more likely to be published, which can lead to an overestimation of overall diagnostic accuracy. To solve this problem, we looked again for further studies by searching the databases and reference lists of primary studies, but could not identify additional relevant articles. Finally, we only included studies written in German, English, or French, which might have aff ected our fi ndings.
The cutoff s that separated patients who had sepsis from those who did not varied greatly between studies. Some had a cutoff that led to the most favourable results for diagnostic accuracy. Others gave sensitivity and specifi city at diff erent thresholds. The diffi culty is that the cutoff s were not subsequently validated. The values of diagnostic accuracy are correlated negatively with each other. To change the cutoff means changing sensitivity at the cost of specifi city or vice versa. False-negative results leading to denial of treatment could be fatal in sepsis. 6 However, to prevent the development of antibiotic resistance, and increased side-eff ects and costs, critically ill patients without bacterial infection should be identifi ed correctly. Thus, a rational threshold is needed. We recommend diff erent phases in testing diagnostic accuracy. First, investigators should examine the validity of procalcitonin in a selected group of patients to fi nd a rational cutoff . Second, to ascertain diagnostic value in everyday clinical practice, the established cutoff has to be validated in a diagnostic controlled trial.
The most important feature of a biomarker is its potential to change clinical decision making. In recent years, cutoff s between 0·1 and 0·5 ng/mL have been calculated in patients with lower respiratory tract infections. 79 Our meta-analysis provides important information for critically ill patients, for whom diagnostic decision making is of upmost importance. The median cutoff of the studies included was 1·1 ng/mL (IQR 0·5-2·0). The absence of a clinical threshold eff ect suggests that a cutoff of between 1·0 and 2·0 ng/mL is helpful for discrimination of patients with sepsis from other infl ammatory conditions, in accordance with recommendations. 80 Likelihood ratios and post-test probabilities are also relevant for clinicians. They provide information about the likelihood that a patient with a positive or negative test actually has sepsis or not. In our study, both likelihood ratio and post-test probability were moderate (fi gure 4). A positive likelihood ratio of 4 implies that a person with disease is four-times more likely to have a positive test result than is a healthy person. Given a pretest probability of 20%, the post-test probability for a positive test result is 48% (fi gure 4). Likewise a negative likelihood ratio of 0·29 reduces the post-test probability to 7% for a negative test result. However, these likelihood ratios are calculated from dichotomised data. The result of the procalcitonin test is either positive or negative. The disadvantage of making data dichotomous is that Positive likelihood ratio Negative likelihood ratio useful information is lost. 81 Because procalcitonin concentrations rise as disease severity advances, 56 patients with a high procalcitonin concentration are more likely to have sepsis than are patients with a low procalcitonin concentration. To provide more precise information about the reliability of the test, we suggest calculating likelihood ratios based on multiple cutoff s.
As our results show, procalcitonin is not a perfect marker for diagnosis of sepsis, but an ideal marker does not exist. Sepsis is a pathophysiological process rather than a specifi c syndrome and is too complex to be described by a single measure. Nevertheless, procalcitonin is one of the most promising parameters. Several other mediators and molecules of the host response to infection-C-reactive protein, soluble TREM1, interleukin 6, interleukin 8, and soluble PLAUR-have been investigated, but with no outstanding result. 23, 35, 40, 82 In conclusion, procalcitonin is a helpful marker for diagnosis of sepsis in critically ill patients. However, it cannot be recommended as the single defi nitive test for sepsis diagnosis, but rather it must be interpreted in context with information from careful medical history, physical examination, and when feasible, microbiological assessment. Moreover, continuing re-evaluation during the course of disease is advisable.
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